S.440 - Preserving Access to Cost Effective Drugs Act116th Congress (2019-2020) |
|Sponsor:||Sen. Cotton, Tom [R-AR] (Introduced 02/12/2019)|
|Committees:||Senate - Judiciary|
|Committee Meetings:||06/27/19 10:00AM 06/20/19 10:00AM|
|Latest Action:||Senate - 06/28/2019 Placed on Senate Legislative Calendar under General Orders. Calendar No. 129. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed Senate
- Passed House
- To President
- Became Law
Summary: S.440 — 116th Congress (2019-2020)All Information (Except Text)
Reported to Senate (06/28/2019)
Preserving Access to Cost Effective Drugs Act or the PACED Act
This bill prohibits patent owners from asserting tribal sovereign immunity as a defense in certain proceedings before the U.S. Patent and Trademark Office, including patent validity challenge proceedings before the Patent Trial and Appeal Board (PTAB). The prohibition also applies to court actions and proceedings before the International Trade Commission.
Sovereign immunity for foreign states shall apply in the PTAB as it applies in federal court. The abrogation of sovereign immunity shall not apply to states or institutions of higher education (i.e., public state universities and institutions).